Compare Davita Inc (DVA) vs Kinder Morgan Inc (KMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Kinder Morgan Inc — how do they compare? Davita Inc trades at $230.55 (market cap $14.92B), while Kinder Morgan Inc trades at $32.5 (market cap $72.40B). The key difference: Kinder Morgan Inc is far larger — about 4.9× Davita Inc's market cap, and Kinder Morgan Inc pays a 3.61% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | KMI | |
|---|---|---|
Market Cap | $14.92B | $72.40B |
Sector | Health | Energy |
52-Week High | $235.71 | $34.31 |
52-Week Low | $103.87 | $25.84 |
Enterprise Value | $27.47B | $104.27B |
Dividend Yield | — | 3.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
KMI trades at $32.24, up 0.37% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.48, and revenue growth is projected to reach $17.5B in 2026. Analyst sentiment is mixed but leans positive, with 47% recommending a buy, supported by a stable dividend and a $10.1B project backlog focused on natural gas infrastructure.
The outlook for KMI is favorable, driven by rising LNG demand and contracted cash flows, though risks include commodity price volatility and high debt levels. The stock offers a solid dividend yield and growth potential from infrastructure investments, making it attractive for income and growth investors despite macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →
